ClinicalTrials.gg
RecruitingNCT05027906Updated Jun 29, 2025

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

A Phase 1/2 interventional study of AT-1501 in Prevention of Rejection in Kidney Transplant, sponsored by Eledon Pharmaceuticals. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Eledon Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.

Planned enrollment
70th of 110
48 · median 79
Started
2022
with 10 others
Phase 1/2
Only one
of the 134
Primary completion
2027-01
later than 12 of 27 live
Registered
105th of 134
by date
Lead sponsor
3 of 134
Eledon Pharmaceuticals

Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 70th largest by planned enrollment of the 110 interventional ones that give a count, is one of 11 that started in 2022, is the only one in phase 1/2, reaches primary completion later than 12 of the 27 other live ones, and was the 105th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Kidney Failure, Chronic with a site in Canada, or all of them as a file.
02

Study summary

This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.

Read the detailed description

This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation. Up to 48 de novo kidney transplant recipients will receive AT-1501 in combination with rATG induction with corticosteroids (CS), and mycophenolate as maintenance therapy.

03

Conditions studied

  • Prevention of Rejection in Kidney Transplant

Keywords

  • Kidney Transplant
  • Renal Allograft Rejection
  • Prophylaxis
  • AT-1501
  • CD40L inhibitor
  • Humanized blocking antibody to CD40L
  • Monoclonal Antibody
  • Renal
  • Transplant
  • ESRD
  • tegoprubart
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. Recipient of their first kidney transplant from a living or deceased donor
  3. Agree to comply with requirements during and for at least 90 days after the last administration of study drug

Exclusion criteria

Exclusion Criteria:

  1. Induction therapy, other than study assigned rATG, planned as part of initial regimen
  2. Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies, with the exception of 5 mg prednisone or equivalent daily;
  3. Previous treatment with AT 1501 or any other anti 0LG therapy
  4. The patient has previously received a bone marrow transplant or any other solid organ transplant, including a kidney, or will be undergoing a multi organ or dual kidney transplant
  5. Will receive a kidney with an anticipated cold ischemia time of > 30 hours;
  6. Will receive a kidney from a donor that meets any of the following criteria:

    • Donation after Cardiac Death (DCD) criteria; or
    • Extended Criteria Donor (ECD) criteria, defined as:
    • Is blood group (ABO) incompatible; or
    • Age ≥ 60 years; or Age 50-59 years with any 2 of the following criteria:
    • Death due to cerebrovascular accident
    • History of hypertension
    • Terminal creatinine ≥ 133 μmol/L (1.5 mg/dL)
  7. Human leukocyte antigen identical (two haplotype match or zero HLA mismatch) donor
  8. Medical conditions that require chronic use of systemic at a dose higher than 5 mg prednisone or equivalent per day
  9. History of a TE event, known hypercoagulable state, or condition requiring long term anticoagulation:
  10. Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    AT-1501 Single Arm

    AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

    Drug: AT-1501

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Incidences

    Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and Adverse Events of Special Interest (AESIs)

    Time frame: Through study completion, an average up to 20 months

  2. Pharmacokinetic- PK profile

    PK profile of the first dose of AT 1501 and at steady state Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (Ct), calculated using noncompartmental analysis (AUC0-t)

    Time frame: Day 1 and at steady state Month 3

  3. Pharmacokinetic- Area under the plasma concentration

    Area under the plasma concentration versus time curve from time 0 extrapolated to infinity, calculated using noncompartmental analysis (AUC0-inf)

    Time frame: Day 1 and at steady state Month 3

  4. Pharmacokinetic- Cmax

    Maximum observed plasma concentration (Cmax)

    Time frame: Day 1 and at steady state Month 3

  5. Pharmacokinetic- Tmax

    Time to reach maximum observed plasma concentration (Tmax)

    Time frame: Day 1 and at steady state Month 3

  6. Pharmacokinetic- Ke

    Terminal elimination rate constant (Ke)

    Time frame: Day 1 and at steady state Month 3

  7. Pharmacokinetic- (t1/2)

    Terminal phase half-life (t1/2)

    Time frame: Day 1 and at steady state Month 3

  8. Pharmacokinetic- CL

    Clearance (CL)

    Time frame: Day 1 and at steady state Month 3

  9. Pharmacokinetic- (Vdss)

    Volume of distribution at steady state (Vdss)

    Time frame: Day 1 and at steady state Month 3

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2027, 59 months after the start.

Of 29 phase 1/2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Aug 30, 2021
StartActual
Feb 18, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05027906
Lead sponsor
Eledon Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Feb 18, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 29, 2025

Study contacts

Eledon Pharmaceuticals
Contact
clinicaltrials@eledon.com
949-238-8090

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprubart

Start the discussion